OS Therapies Updates on Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

Source :: Entertainment Close-up. June 6, 2024
Publication Year :: 2024
Abstract: OS Therapies, a clinical-stage oncology-focused immunotherapy company developing cancer vaccines and antibody drug conjugate (ADC) therapeutic candidates, reported a positive clinical update for AOST-2121 (NCT04974008), its ongoing Phase 2b clinical [...]

Subjects :: Biological products industry -- Product development
Operating systems -- Product development
Osteosarcoma -- Health aspects
Cancer -- Care and treatment
Clinical trials -- Health aspects
Cancer vaccines -- Product development
64-bit operating system
32-bit operating system
Operating system
Arts and entertainment industries

Tools